HGH (191aa somatropin) research and evidence overview

Somatropin—recombinant human growth hormone, the 191-amino-acid sequence identical to the pituitary hormone—has better evidence behind it than almost anything else in this catalog, and that evidence is almost entirely about people who are deficient in it. In adults with diagnosed growth hormone deficiency, placebo-controlled trials pooled by meta-analysis show reproducible changes in body composition and lipids. In healthy, fit young adults, the best-designed systematic review found lean body mass increases with no measurable improvement in strength or exercise capacity, alongside more side effects.

Those two findings are frequently blurred together in marketing. They come from different populations, different doses, and different endpoints.

A meta-analysis in Pituitary (PMID 24810900) screened 173 publications and included 28 reports covering 22 randomized, double-blind, placebo-controlled trials of at least six months' duration: 591 GH-treated patients against 562 on placebo. The pooled results:

• Lean body mass rose 2.61 kg on GH versus 0.04 kg on placebo (p<0.0001).
• Fat mass fell 2.19 kg versus a 0.31 kg gain on placebo (p=0.0002).
• Total cholesterol fell 0.38 mmol/L versus 0.01 on placebo (p<0.0001); LDL fell 0.42 versus 0.10 mmol/L (p=0.0009).
• Body-composition changes were dose-related—higher doses outperformed lower ones—but the lipid improvements were not dose-dependent, appearing equally at low and high doses.

That last point is the interesting one. It means the dose–response relationship differs by endpoint, so "more is better" holds for one outcome and not another even within the population the drug is approved for.

The reference study for non-medical use is a systematic review in Annals of Internal Medicine (PMID 18347346). It searched four databases through 2007 and included 44 articles describing 27 study samples, in which 303 participants received growth hormone—a total of 13.3 person-years of treatment. Participants were young (mean age 27), lean (mean BMI 24), and fit (mean VO2max 51 mL/kg/min).

• Lean body mass increased 2.1 kg (95% CI 1.3–2.9) versus untreated participants.
• Strength and exercise capacity did not appear to improve.
• Lactate during exercise was significantly higher in two of the three studies measuring it—the opposite of an endurance benefit.
• Soft-tissue edema and fatigue were both more frequent in GH recipients.

The reviewers flagged two limitations that cut in opposite directions: few studies measured athletic performance at all, and the protocols studied (mean 36 µg/kg/day for a mean of 20 days) may not reflect the doses and durations used in practice. The frequently repeated claim that GH is performance- enhancing in healthy athletes is, on this evidence, not supported—while the lean-mass change that fuels the claim is real and measurable.

Somatropin is a prescription biologic. The approved indications for one widely used product (Norditropin labeling, DailyMed) are, in pediatric patients, growth failure from inadequate endogenous GH secretion, short stature associated with Noonan or Turner syndrome, short stature in children born small for gestational age without catch-up growth, idiopathic short stature with a height SDS below −2.25, and growth failure due to Prader-Willi syndrome; and in adults, replacement of endogenous GH in growth hormone deficiency. Other somatropin products carry additional indications such as HIV-associated wasting or short bowel syndrome.

Anti-aging, bodybuilding, and general "optimization" appear on no somatropin label. In the United States, distributing human growth hormone for uses other than those approved by the FDA is restricted by statute—an unusual provision, since most off-label prescribing carries no criminal exposure. Growth hormone is also prohibited at all times, in and out of competition, under the World Anti-Doping Code.

When a somatropin study is cited, the decisive question is whether the participants were deficient. Restoring a hormone to normal in someone lacking it and adding it to someone with normal levels are pharmacologically different experiments with different results, and the deficiency literature is far larger and more favorable than the healthy-subject literature. Dose and duration matter next: the athletic studies averaged 20 days, which says nothing about years of use.